A life sciences company hiring a senior leader is usually hiring for a version of the organization that does not exist yet. More often than not, the stage it is entering demands capabilities the current team has never had to use, which is what makes pharmaceutical executive search different from filling a standard leadership seat.

PIXCELL is a generalist executive search firm recruiting senior leaders across pharmaceutical and life sciences as well as financial services, information technology and digital transformation, manufacturing and engineering, retail and distribution, real estate and construction, professional services, and the public and parapublic sectors. This article walks through what changes at each stage of growth in pharmaceutical and biotech recruiting, which roles carry the weight at each one, and what a life sciences executive search partner has to be able to do for your organization.

Why Hiring in Life Sciences Breaks the Normal Rules of Executive Recruitment

Three things make life sciences executive search different from other sectors. The first is the size of the field. A mandate here is rarely defined as a vice president of regulatory affairs. It is defined as a vice president of regulatory affairs who has carried a biologic through a specific pathway, in a therapeutic area, at a company of roughly this stage. Each qualifier removes candidates. What remains is often measured in dozens worldwide rather than hundreds, which is why these searches are built first by research rather than by working a network, and why we start them with a talent map rather than a job posting.

The second is that scientific credibility is usually a hard requirement rather than a preference, and at this level, it cannot be acquired on the job. A chief medical officer who cannot hold a room of investigators, or a regulatory lead who cannot defend a position to an agency reviewer, will not grow into it after the hire. The underlying odds explain the caution: Research published in Biostatistics puts the probability that a drug entering phase one eventually reaches approval at 13.8 percent. The right leader is critical for success.

The third is that a wrong hire compounds on a timeline that will not move to accommodate a restart. Deloitte's 2025 analysis of pharmaceutical innovation puts the average cost of bringing an asset from discovery to launch at 2.67 billion dollars, against a projected return on research and development investment of 7.0 percent. Nine months of the wrong leadership is charged against that math, making a pharmaceutical or biotech mis-hire one of the most costly ones.

Three practical consequences follow. Searches here are research-led rather than network-led. Assessment has to test judgment under regulatory constraint rather than general leadership. And the timeline conversation belongs at the briefing rather than at the shortlist, because a field this narrow rarely produces candidates on a standard schedule. 

Read more: Executive Search in the Pharmaceutical and Life Sciences

The Leadership a Clinical-Stage Company Actually Needs

Before approval, four seats carry most of the weight. Biotech executive search at this stage is largely a question of getting them in the right order.

• Chief medical officer. Owns the clinical strategy and is the company's voice to investigators, regulators and, increasingly, investors. This is the seat where scientific judgment and external credibility have to sit in the same person.
• Head of regulatory affairs. Owns the pathway. What the agency will accept as evidence, and what sequence of interactions gets there without resetting the timeline.
• Head of clinical operations. Owns execution across sites, enrollment, vendors and data quality. A trial that misses enrollment is usually an operations failure rather than a science failure.
• Chief scientific officer. Increasingly a separate seat from the founder, accountable for the research engine beyond the lead program.

At this stage, a company is often hiring people more experienced than anyone currently in it, which changes the dynamic of the search. The candidates worth having are assessing the science and the company as carefully as the board is assessing them. A biotech headhunter who can describe the mechanism but not the financing, or the financing but not the data, loses the conversation in the first call.

"The world is very small in specific pharmaceutical and therapeutic fields," says François Piché-Roy, President and Managing Partner at PIXCELL. "Discretion is not a courtesy in this sector, but a requirement, and it’s one that we take seriously. We also need to be extremely professional to gain candidate trust and ensure they respond to our outreach."

The founder question deserves a direct answer. A scientific founder recruiting a first operating executive is deciding how much control to give away, and that decision is too often made late, at offer stage, after months of work. The time to settle it is before the mandate starts: what the new executive decides alone, what the founder keeps, and what goes to the board.

Read more: When to Choose an Industry Insider vs. an Outsider for Your Executive Team

What Changes When a Company Reaches Approval and Commercial Launch

Approval does not expand a company. It converts one. The organization that ran the trials now has to price a product, defend that price to payers, supply it reliably and answer for quality, and almost none of the leadership that got it there has run a launch.

The scale of that gap shows up in the launch data. Of the 96 launches forecast to pass one billion dollars in annual sales between 2022 and 2026, McKinsey counted 61 from companies that had never brought a product to market before. First-time launchers are now the majority of the field, competing against organizations with launch muscle memory.

Four seats appear, usually inside a compressed window.

• The chief commercial officer owns the revenue plan and the commercial organization that does not exist yet. 
• The head of manufacturing and supply owns the shift from clinical supply to commercial volume, at commercial reliability. 
• The head of quality owns the systems an inspector will examine. 
• And the head of market access and reimbursement owns whether the product is paid for at all, which is the role most often underestimated and the one where Canadian experience is genuinely distinct.

 
Biotech executive search at this point turns less on sector knowledge than on launch experience, which is a far smaller pool.

The commercial urgency across the sector is real. PwC estimates that more than 300 billion dollars of branded pharmaceutical revenue is exposed to loss of exclusivity this decade, which is why commercial leadership is being hired hard and early.

Then comes the decision companies make too late: Which of the current leaders scale into the commercial phase, and which do not? A search partner is often asked to assess incumbents alongside external candidates at this point, and that is legitimate work rather than a signal of bad faith. It is how a board reaches an answer it can defend to the people it affects. We set out the method separately in how executive assessment reduces the risk of a senior mis-hire.

Medical device companies follow a compressed version of the same arc. Approval pathways are shorter, but the commercial build is just as abrupt, and the clinical and commercial seats often have to be filled inside a single hiring cycle.

Recruiting Pharmaceutical Leadership in Quebec and Canada

Quebec carries a concentration of pharmaceutical and biotech activity that is easy to underestimate from outside the country. Montreal International counts more than 1,300 life sciences and health technology companies in the province, over 58,000 jobs, and more than 250 specialized research organizations. Multinational subsidiaries, contract research organizations and a dense research institute base sit within a short radius of one another.

Medical device companies sit inside that same cluster. These constraints follow for anyone hiring senior leadership in the province. 

French-language capability is frequently a real operating requirement rather than a preference, and it narrows a field that is already narrow. It needs to be settled honestly at the briefing, with a clear answer on what the role genuinely requires in French and on day one versus within a year.

Canadian market access experience does not transfer cleanly from a United States career, because reimbursement runs provincially. The Patented Medicine Prices Review Board found that new drugs took an average of 906 days between Health Canada authorization and a first public plan listing, with drugs facing no delaying factors averaging 518 days against 1,179 for those facing one or more. A leader who has worked that system is not interchangeable with one who has worked a United States payer market.

The realistic field for most senior roles here is international. That makes relocation, work authorization and family considerations part of the search from the first conversation rather than an afterthought at the offer stage. PIXCELL runs these mandates as Montreal headhunters with international executive search reach through the CFR Global Executive Search network, which matters when the credible field for one role sits across four countries.

What to Ask a Search Firm Before You Give It a Life Sciences Mandate

The most useful conversation with pharmaceutical executive search firms and life science executive search firms is the one with more questions than claims. These are the questions worth raising in a first meeting with any of the life sciences executive recruiters you are considering.

1. Which therapeutic areas and which company stages have you actually worked in? Sector experience stated at the level of life sciences means very little. Oncology at clinical stage and vaccines at commercial stage are different markets with different people in them. When you compare headhunters, pharmaceutical industry depth and biotech depth are not the same thing.
2. How will you build the field for this role? Expect an answer about research and mapping. Pharmaceutical recruiters who answer with the size of a database are describing a contact list rather than a market.
3. What will you tell us about the candidates who decline? In a field this narrow, the refusals carry as much information as the shortlist, on compensation, on reputation, on how the opportunity reads from outside.
4. How do you assess scientific and regulatory judgment, as distinct from general leadership? The two are often lumped together, but they’re distinct, and both are key.
5. Who is off-limits to you because of existing client relationships? This matters more here than in broader sectors, because the pool is small enough that a few protected companies can remove the obvious candidates.
6. How do you reach candidates outside Canada, and what does that mean practically? Ask what happens after the first call, on work authorization, relocation and timing.

"In pharma and biotech, how you handle a candidate journey is very important, even with the ones who don’t work out," says Piché-Roy. "In this sector, chances are that you will meet that person again. Handling the process properly is the only way a field this small stays open to you."

Read more: How Long Does an Executive Search Typically Take?

Conclusion

The right leader for a life sciences company needs to be defined by the stage the company is entering, not the stage it is leaving. Most hiring mistakes in this sector are stage mistakes rather than candidate mistakes. 

Three things are worth underlining: The credible field is narrow and has to be researched rather than sourced. The requirement changes sharply at approval, when a research organization becomes a commercial one. And the Canadian market adds language and reimbursement constraints that a generic search will miss. 

PIXCELL is a generalist executive search firm recruiting senior leaders across eight sectors, with pharmaceutical executive search among them. If a leadership change is on your horizon, start with a conversation about the role rather than a mandate. Contact PIXCELL to begin that conversation.

Frequently Asked Questions

What does a pharmaceutical executive search firm do differently from a general recruiter?
It builds the field by research rather than by sourcing, because the credible candidates are employed, rarely looking, and often identifiable only through program history rather than job titles. It also assesses scientific and regulatory judgment as a distinct capability, not as a variant of general leadership.

When should a biotech company hire its first commercial leader?
Earlier than most boards assume, and ideally before the approval decision rather than after it. Pricing, payer strategy and the commercial organization all take longer to build than a search does, and hiring after approval means launching while the leader is still learning the asset.

Does regulatory experience transfer between therapeutic areas?
Partly. The habits of agency interaction and evidence strategy transfer well. The specifics of a pathway, an endpoint set and a precedent base often do not, which is why a shortlist built on the word regulatory alone tends to collapse at interview.

How long does an executive search in life sciences take?
Longer than a comparable search in a broader sector, because the field is smaller and more of it has to be approached individually. The honest version of that estimate belongs at the briefing, alongside an agreed view of which requirements are genuinely non-negotiable.